Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 2, 2012, authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 450,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,456 pence per share; lowest price paid was 1,437.5 pence per share.
- Treasury Holdings (Settled): 501,165,427 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,515,427 shares (10.19% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,943,188,600 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 450,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.19% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (501,165,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,943,188,600 shares in issue) for disclosure threshold assessments under FSA rules.
- Check subsequent filings for the settlement status of the 2,350,000 shares included in the "unsettled" treasury count.
- Note that this filing does not contain operational financial results; refer to the most recent Form 20-F or interim report for revenue and earnings data.